Natural history of t(11;14) multiple myeloma.
Natural history of t(11;14) multiple myeloma.
- 2018
Translocation (11;14) on interphase FISH in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma (MM) based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 with no chromosomal translocation. The median progression-free survival (PFS) for the three groups were 23.0 (95% CI, 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months respectively [P<0.01]. The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months respectively [P<0.01]. Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months respectively [p P<0.01]. The above relationship held true in patients with age <65 years, ISS I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio [HR]: 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM is inferior to other standard risk patients.Leukemia accepted article preview online, 27 June 2017. doi:10.1038/leu.2017.204.
English
0887-6924
*Chromosomes, Human/ge [Genetics]
*Multiple Myeloma/ge [Genetics]
*Multiple Myeloma/pa [Pathology]
Adult
Aged
Aged, 80 and over
Chromosome Aberrations
Female
Humans
In Situ Hybridization, Fluorescence/mt [Methods]
Male
Middle Aged
Neoplasm Staging/mt [Methods]
Prognosis
Translocation, Genetic/ge [Genetics]
Young Adult
MedStar Washington Hospital Center
Medicine/Internal Medicine
Journal Article
Translocation (11;14) on interphase FISH in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma (MM) based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 with no chromosomal translocation. The median progression-free survival (PFS) for the three groups were 23.0 (95% CI, 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months respectively [P<0.01]. The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months respectively [P<0.01]. Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months respectively [p P<0.01]. The above relationship held true in patients with age <65 years, ISS I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio [HR]: 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM is inferior to other standard risk patients.Leukemia accepted article preview online, 27 June 2017. doi:10.1038/leu.2017.204.
English
0887-6924
*Chromosomes, Human/ge [Genetics]
*Multiple Myeloma/ge [Genetics]
*Multiple Myeloma/pa [Pathology]
Adult
Aged
Aged, 80 and over
Chromosome Aberrations
Female
Humans
In Situ Hybridization, Fluorescence/mt [Methods]
Male
Middle Aged
Neoplasm Staging/mt [Methods]
Prognosis
Translocation, Genetic/ge [Genetics]
Young Adult
MedStar Washington Hospital Center
Medicine/Internal Medicine
Journal Article